Neoleukin Therapeutics (NASDAQ: NLTX)
Some price data may be temporarily unavailable.
Neoleukin Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Neoleukin Therapeutics Company Info
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
News & Analysis
Why Neoleukin Therapeutics Stock Is Down Today
The company is experiencing regulatory headwinds.
Is Neoleukin Therapeutics a Buy?
The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.
Is It Too Late to Buy These 3 Pharmaceutical Stocks?
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
Here's Why Neoleukin Therapeutics Dropped Today
The development-stage drug company announced the pricing of a public offering of common stock.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.